Scarica l'app Stockscreener
105.88
1.97%
-2.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NUVL Giù?
Forum
Previsione
Nuvalent Inc Borsa (NUVL) Ultime notizie
FDA accepts NDA for Nuvalent's zidesamtinib for non-small cell lung cancer - MSN
Four companies raise nearly $950M in follow-ons: Public Equity Report - BioCentury
Nuvalent Announces $500M Stock Offering Pricing - The Globe and Mail
Biotech Stock Gets Booted in Latest Fund Update - AOL.com
Will Nuvalent Inc. stock keep outperforming rivalsJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Why analysts upgrade Nuvalent Inc. stockJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
Sidley Represents Nuvalent in Pricing of US$500 Million Public Offering - Legal Desire Media and Insights
Jefferies raises Nuvalent stock price target to $164 on promising cancer drug data - Investing.com Nigeria
[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC - The Malaysian Reserve
Can Nuvalent Inc. stock surprise with earnings upsideWeekly Trade Report & Safe Capital Growth Plans - newser.com
Will Nuvalent Inc. stock reach Wall Street targetsPortfolio Return Report & Accurate Buy Signal Notifications - newser.com
FDA accepts Nuvalent’s zidesamtinib application for lung cancer treatment By Investing.com - Investing.com Nigeria
Nuvalent Insider Sold Shares Worth $2,065,030, According to a Recent SEC Filing - MarketScreener
Nuvalent Gets FDA Review of Zidesamtinib for ROS1-Positive Lung Cancer - MarketScreener
Nuvalent Executives Sell Over $4.6 Million in Stock - TradingView
CFO Balcom Sells 20,729 ($2.1M) Of Nuvalent Inc [NUVL] - TradingView
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
[424B5] Nuvalent, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Nuvalent announces FDA acceptance of new drug application for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC - MarketScreener
Can Nuvalent Inc. stock rebound after recent weaknessJuly 2025 Pullbacks & Weekly High Conviction Trade Ideas - newser.com
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Nuvalent (NUVL) - The Globe and Mail
Using economic indicators to assess Nuvalent Inc. potentialStock Surge & Free Technical Confirmation Trade Alerts - newser.com
What momentum indicators show for Nuvalent Inc. stockJuly 2025 Gainers & Safe Capital Growth Stock Tips - newser.com
Nuvalent Prices $500 Million Common Stock Offering - MarketScreener
Nuvalent prices $500 million public offering at $101 per share By Investing.com - Investing.com Nigeria
Nuvalent Announces Pricing of Public Offering of Common Stock - Finviz
Nuvalent prices $500 million public offering at $101 per share - Investing.com India
Nuvalent prices 4.95 million shares in public offering at $101.00 per share - MarketScreener
Nuvalent Prices 4.95 Million Shares In Public Offering At $101.00 Per Share - TradingView
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):